ARWR News and Press, Arrowhead Pharmaceuticals Inc. From 10/03/22

Summary My portfolio, built specifically for my retirement ~20+ years from now, had a crushing September, along with the rest of the market, in spite of amazing Petrobras dividends. Making monthly contributions, even though they seem small at the time, makes all the difference in ...

Summary Arrowhead is an RNA-interference drug developer with a potentially best-in-class platform in TRiM. The company has attracted five major pharmaceutical partners in Janssen, Amgen, Takeda, GSK and Horizon Therapeutics. After a dull 12 months there will be at least 12 cli...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: European Respiratory Society (ERS) International Congress 2022 – September 4-6, 2022 Title: Silencing MMP7 expression with a lung-tar...

Summary Shares of Horizon Therapeutics are down 50% from last year's highs, a consequence of a prolonged biotech market and recent setbacks. The Tepezza growth scare is the main reason the stock is trading at current levels, but Tepezza remains well-positioned for long-term growth...

JNJ tends to announce big news at yearly fall conference, which might be a catalyst for partnered Arrowhead Pharmaceuticals this fall. JNJ's collaboration project with Arrowhead could be ready for Phase 3 at any time, potentially triggering future milestone payments. Connect the d...

Arrowhead Pharmaceuticals ( NASDAQ: ARWR ) said filed an application to get clearance to start a phase 1/2a trial of ARO-MMP7 to treat idiopathic pulmonary fibrosis (IPF). The company added that it filed application to a local Ethics Committee and to the New Zealand Me...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-MMP7, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce expression of matrix metalloprote...

Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Shares of Baron Global Advantage Fund (the “Fund”) declined 32.3% (Institutional Shares) during the second ...

Image source: The Motley Fool. Arrowhead Pharmaceuticals (NASDAQ: ARWR) Q3 2022 Earnings Call Aug 04, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Arrowhead Pharmaceuticals (ARWR) Q3 2022 Earnings Call Transcript...

Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2022 Results Conference Call August 4, 2022 05:00 PM ET Company Participants Vince Anzalone - VP, IR Christopher Anzalone - President and CEO Javier San Martin - Chief Medical Officer Ken Myszkowski - CFO James Ha...